Therapeutic uses of Dunaliella powder

• US 7,264,813 B2
• Filed: 09/24/2003
• Issued: 09/04/2007
• Est. Priority Date: 09/24/2003
• Status: Expired due to Term

• Current Assignee: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure And Services Ltd.
• Original Assignee: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure And Services Ltd.
• Inventors: Shaish, Aviv, Harats, Dror
• Primary Examiner(s): FLOOD, MICHELE C
• Application Number:
  US10/668,601
• Publication Number:
  US 20050063991A1
• Time in Patent Office: 1,441 Days
• Field of Search: 424/195.15, 424/451, 424/489, 514/824, 514/866
• US Class Current: 424/195.17
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/426 1,3-Thiazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 36/05 Chlorophycota or chlorophyta (green algae), e.g. Chlorella
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating. to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear receptors.

Claims

1. A method for reducing insulin and/or glucose plasma levels in a subject afflicted with diabetes, comprising administering to the subject an effective amount of dried Dunaliella algae, thereby reducing plasma insulin and/or glucose plasma levels in the subject.

2. The method according to claim 1 wherein the dried Dunaliella algae is administered together with one or more activators of nuclear receptors.

3. The method according to claim 2 wherein the activators of nuclear receptors are peroxisome proliferator-activated receptor α

or γ

(PPARα

or PPARγ

) agonists.

4. The method according to claim 3 wherein the PPARα

or PPARγ

agonists are selected from the group consisting of fibrates and thiazolidinediones.

5. The method according to claim 4 wherein the fibrates are selected from the group consisting of clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate, and gemfibrozil.

6. The method according to claim 4 wherein the thiazolidinediones are selected from the group consisting of troglitazone, BRL 49653, pioglitazone, ciglitazone, WAY-120,744, englitazone, AD 5075, darglitazone, and rosiglitazone.

7. The method according to claim 1 wherein the dried Dunaliella algae is administered orally.

8. The method according to claim 1 wherein the dried Dunaliella algae is obtained from Dunaliella bardawil.

9. The method according to claim 1, wherein the dried Dunaliella algae is encapsulated.

10. The method according to claim 1, wherein the dried Dunaliella algae comprises β

-carotene.

11. The method according to claim 10, wherein the β

-carotene comprises 9-cis β

-carotene.

12. The method according to claim 10, wherein the β

-carotene comprises an approximate 1;

1 ratio of all-trans β

-carotene and 9-cis β

-carotene.